Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

Authors :: Preudhomme, Claude
Guilhot, Joelle
Nicolini, Franck Emmanuel
Guerci-Bresler, Agnes
Rigal-Huguet, Francoise
Eclache, Virginie
Mahon, Francoise-Xavier
Guilhot, Francoise
Corm, Selim
Etienne, Gabriel
Roche-Lestienne, Catherine
Delmer, Alain
Rousselot, Philippe
Legros, Laurence
Berger, Marc
Vekhoff, Anne
Rea, Delphine
Jourdan, Eric
Allard, Christian
Coiteux, Valerie
Gardembas, Martine
Berthou, Christian
Maloisel, Frederic
Source :: The New England Journal of Medicine. Dec 23, 2010, Vol. 363 Issue 26, p2511, 11 p.
Publication Year :: 2010
Abstract: A study was conducted to evaluate the efficacy of Imatinib plus peginterferon alfa-2a in the treatment of chronic myeloid leukemia (CML). Results indicated that such a form of treatment resulted in significantly higher rates of molecular response in such patients.

Tools